Recombinant Human CTSK Protein (Ala115-Met329), His tagged

• Cat.No.: CTSK-1890H
• Product Overview: Recombinant human CTSK (Ala115-Met329) fused with His tag was expressed in E. coli.

Specification

• Description: Thiol protease involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation. Involved in the release of thyroid hormone thyroxine (T4) by limited proteolysis of TG/thyroglobulin in the thyroid follicle lumen.
• Source: E. coli
• Species: Human
• Tag: His
• Form: Lyophilized powder/frozen liquid
• Molecular Mass: 25.81 kDa
• Protein length: Ala115-Met329
• Purity: >90% as determined by SDS-PAGE
• Notes: For research use only.
• Storage: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 centigrade for one week. Store at -20 to -80 centigrade for twelve months from the date of receipt.
• Storage Buffer: Lyophilized from PBS, pH 7.4, 0.02% NLS, 1mM EDTA, 4% trehalose, 1% mannitol.
• Reconstitution: Reconstitute in sterile water for a stock solution.
• Shipping: They are shipped out with dry ice/blue ice unless customers require otherwise.

Gene Information

• Gene Name: CTSK cathepsin K [ Homo sapiens (human) ]
• Official Symbol: CTSK
• Synonyms: CTSK; cathepsin K; cathepsin K (pycnodysostosis), CTSO, CTSO2, PYCD; PKND; cathepsin O; cathepsin X; cathepsin O1; cathepsin O2; CTSO; PYCD; CTS02; CTSO1; CTSO2; MGC23107
• Gene ID: 1513
• mRNA Refseq: NM_000396
• Protein Refseq: NP_000387
• MIM: 601105
• UniProt ID: P43235

Reviews

09/13/2019

This guidance can help researchers design and execute their experiments more effectively, ensuring reliable and accurate results.

01/27/2019

They have a deep understanding of the CTSK protein and can provide valuable insights into its characteristics, properties, and optimal experimental conditions.

12/14/2016

the manufacturer offers outstanding technical support, serving as a valuable resource to resolve any issues that may arise during my research.

Q&As

Can CTSK be a target for the development of novel therapeutics for periodontal diseases?

Yes, CTSK inhibitors are being investigated for their potential in preventing bone loss associated with periodontal diseases.

How does CTSK contribute to the progression of atherosclerosis, and can it be a therapeutic target for cardiovascular diseases?

CTSK has been linked to vascular calcification in atherosclerosis, and inhibiting its activity may have potential as a therapeutic strategy for cardiovascular diseases.

How might CTSK inhibitors impact the treatment landscape for bone metastasis in cancer patients?

CTSK inhibitors could potentially be used to limit bone destruction in cancer patients with bone metastasis, improving their quality of life.

Are there any other medical conditions where CTSK inhibitors could be beneficial?

CTSK inhibitors are being explored for potential therapeutic applications in conditions like rheumatoid arthritis and certain cancers due to their involvement in tissue remodeling.

Are there diagnostic applications for CTSK in identifying bone-related disorders?

While CTSK is not currently used as a diagnostic marker, its levels and activity could potentially be explored for diagnostic purposes in the future.